Oberweis Asset Management Inc. Purchases 36,200 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Oberweis Asset Management Inc. lifted its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 18.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 237,200 shares of the company's stock after purchasing an additional 36,200 shares during the period. Oberweis Asset Management Inc. owned 0.33% of Kiniksa Pharmaceuticals worth $4,692,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Voya Investment Management LLC increased its position in Kiniksa Pharmaceuticals by 16.8% in the fourth quarter. Voya Investment Management LLC now owns 19,988 shares of the company's stock worth $395,000 after buying an additional 2,870 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Kiniksa Pharmaceuticals by 23.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,111 shares of the company's stock worth $299,000 after acquiring an additional 2,881 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Kiniksa Pharmaceuticals by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after acquiring an additional 4,575 shares during the period. MetLife Investment Management LLC lifted its holdings in Kiniksa Pharmaceuticals by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after purchasing an additional 1,374 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Kiniksa Pharmaceuticals by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock worth $15,262,000 after purchasing an additional 29,300 shares during the period. Institutional investors own 53.95% of the company's stock.

Insider Activity at Kiniksa Pharmaceuticals

In other news, insider Ross Moat sold 18,259 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $20.29, for a total value of $370,475.11. Following the completion of the sale, the insider now owns 9,415 shares of the company's stock, valued at approximately $191,030.35. This represents a 65.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Eben Tessari sold 14,000 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 110,025 shares of company stock valued at $2,372,610 over the last three months. 54.57% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Wedbush reiterated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $38.00.

Kiniksa Pharmaceuticals Trading Up 3.6 %

Shares of Kiniksa Pharmaceuticals stock traded up $0.94 during trading on Wednesday, hitting $26.82. The stock had a trading volume of 590,783 shares, compared to its average volume of 472,963. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $17.38 and a 12 month high of $28.15. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -191.56 and a beta of 0.31. The business's 50-day moving average is $21.31 and its 200 day moving average is $21.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company's quarterly revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.25) EPS. As a group, equities analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.